3TC (Lamivudine, Epivir): Research
- A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice-Daily and Once-Daily Dosing in HIV-1 Infected Individuals (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Evaluation of Novel Combination of Abacavir, Lamivudine and Efavirenz (July 12, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
- Once-a-Day Therapy for HIV Infection (July 11, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
- Efavirenz + Zidovudine + Lamivudine Provides Superior Long-Term HIV-RNA Suppression, Antiretroviral Activity and Tolerability Versus Indinavir + ZDV + 3TC: Results of Study 006 at 72 Weeks (Initial Cohort) (November 19, 1999)
In The 37th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Characterization of Lamivudine Pharmacokinetics in Cerebrospinal Fluid and Plasma by Ultra-Intensive Sampling (November 19, 1999)
In The 37th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- A Study in HIV Positive Women of Quadruple Therapy: Nelfinavir, Saquinavir, Stavudine, and Lamivudine (February 4, 1998)
From Seattle Treatment Education Project
- Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm3 (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- ICAAC Update: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (Winter 1996/1997)
In STEP Perspective, from Seattle Treatment Education Project
- Final Results of CAESAR Study Demonstrate a Survival Benefit with 3TC (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- d4T and 3TC Combination Studies Confirm the Effect of the Combination (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- 3TC Clinical Benefit: More Data Presented (October 4, 1996)
In AIDS Treatment News, from AIDS Treatment News
|
Advertisement
|
Email
Glossary
